JP2005522293A - 生物学的組織の分光法のための系および方法 - Google Patents
生物学的組織の分光法のための系および方法 Download PDFInfo
- Publication number
- JP2005522293A JP2005522293A JP2003584690A JP2003584690A JP2005522293A JP 2005522293 A JP2005522293 A JP 2005522293A JP 2003584690 A JP2003584690 A JP 2003584690A JP 2003584690 A JP2003584690 A JP 2003584690A JP 2005522293 A JP2005522293 A JP 2005522293A
- Authority
- JP
- Japan
- Prior art keywords
- probe
- collection
- raman
- tissue
- fiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 112
- 238000004611 spectroscopical analysis Methods 0.000 title description 11
- 238000001069 Raman spectroscopy Methods 0.000 claims abstract description 366
- 239000000523 sample Substances 0.000 claims abstract description 347
- 210000001519 tissue Anatomy 0.000 claims abstract description 339
- 239000000835 fiber Substances 0.000 claims abstract description 265
- 230000003287 optical effect Effects 0.000 claims abstract description 81
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 74
- 239000013307 optical fiber Substances 0.000 claims abstract description 48
- 238000005259 measurement Methods 0.000 claims abstract description 25
- 230000005855 radiation Effects 0.000 claims abstract description 10
- 210000000481 breast Anatomy 0.000 claims description 115
- 230000003595 spectral effect Effects 0.000 claims description 86
- 238000009826 distribution Methods 0.000 claims description 58
- 210000000497 foam cell Anatomy 0.000 claims description 49
- 210000001367 artery Anatomy 0.000 claims description 48
- 238000004458 analytical method Methods 0.000 claims description 45
- 238000001727 in vivo Methods 0.000 claims description 25
- 238000012545 processing Methods 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 150000002632 lipids Chemical class 0.000 claims description 13
- 208000007536 Thrombosis Diseases 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- 210000004969 inflammatory cell Anatomy 0.000 claims description 4
- 230000001902 propagating effect Effects 0.000 claims description 2
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 abstract description 33
- 208000029078 coronary artery disease Diseases 0.000 abstract description 7
- 208000014674 injury Diseases 0.000 abstract description 3
- 230000008733 trauma Effects 0.000 abstract description 3
- 210000004872 soft tissue Anatomy 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 description 366
- 230000000877 morphologic effect Effects 0.000 description 194
- 238000001237 Raman spectrum Methods 0.000 description 164
- 102000008186 Collagen Human genes 0.000 description 104
- 108010035532 Collagen Proteins 0.000 description 104
- 230000005284 excitation Effects 0.000 description 104
- 229920001436 collagen Polymers 0.000 description 103
- 239000000126 substance Substances 0.000 description 102
- 208000004434 Calcinosis Diseases 0.000 description 94
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 87
- 230000003902 lesion Effects 0.000 description 68
- 230000003211 malignant effect Effects 0.000 description 57
- 210000004351 coronary vessel Anatomy 0.000 description 54
- 210000004027 cell Anatomy 0.000 description 52
- 239000000203 mixture Substances 0.000 description 52
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 51
- 235000012000 cholesterol Nutrition 0.000 description 45
- 230000003143 atherosclerotic effect Effects 0.000 description 41
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 40
- 238000000513 principal component analysis Methods 0.000 description 37
- 230000000875 corresponding effect Effects 0.000 description 36
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 34
- 239000011575 calcium Substances 0.000 description 34
- 229910052791 calcium Inorganic materials 0.000 description 34
- 102000004169 proteins and genes Human genes 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 34
- 108020004414 DNA Proteins 0.000 description 33
- 239000013078 crystal Substances 0.000 description 33
- 230000001338 necrotic effect Effects 0.000 description 31
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 30
- 239000011648 beta-carotene Substances 0.000 description 30
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 30
- 235000013734 beta-carotene Nutrition 0.000 description 30
- 229960002747 betacarotene Drugs 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 30
- 239000008280 blood Substances 0.000 description 30
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 30
- 230000002308 calcification Effects 0.000 description 28
- 239000000047 product Substances 0.000 description 28
- 201000010099 disease Diseases 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 210000000805 cytoplasm Anatomy 0.000 description 26
- 210000003855 cell nucleus Anatomy 0.000 description 25
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 25
- 238000004422 calculation algorithm Methods 0.000 description 24
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 24
- 230000001965 increasing effect Effects 0.000 description 23
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 22
- 239000002585 base Substances 0.000 description 21
- 238000013461 design Methods 0.000 description 21
- 238000000338 in vitro Methods 0.000 description 21
- 229910000019 calcium carbonate Inorganic materials 0.000 description 20
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 18
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 18
- 238000010521 absorption reaction Methods 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 210000002744 extracellular matrix Anatomy 0.000 description 18
- 230000006870 function Effects 0.000 description 18
- 206010006187 Breast cancer Diseases 0.000 description 16
- 208000026310 Breast neoplasm Diseases 0.000 description 16
- 230000001413 cellular effect Effects 0.000 description 16
- 238000003384 imaging method Methods 0.000 description 16
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 16
- 229910052594 sapphire Inorganic materials 0.000 description 16
- 239000010980 sapphire Substances 0.000 description 16
- 229910019142 PO4 Inorganic materials 0.000 description 15
- 210000001789 adipocyte Anatomy 0.000 description 15
- 238000001574 biopsy Methods 0.000 description 15
- 239000010452 phosphate Substances 0.000 description 15
- 235000021317 phosphate Nutrition 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 206010001233 Adenoma benign Diseases 0.000 description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 206010061818 Disease progression Diseases 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 14
- 230000005750 disease progression Effects 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 229910001868 water Inorganic materials 0.000 description 14
- 102000007469 Actins Human genes 0.000 description 13
- 108010085238 Actins Proteins 0.000 description 13
- BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 13
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 13
- 238000012774 diagnostic algorithm Methods 0.000 description 13
- 238000009607 mammography Methods 0.000 description 13
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 13
- 229940117972 triolein Drugs 0.000 description 13
- 208000007659 Fibroadenoma Diseases 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 150000001408 amides Chemical class 0.000 description 12
- 201000003149 breast fibroadenoma Diseases 0.000 description 12
- 150000001840 cholesterol esters Chemical class 0.000 description 12
- 238000011161 development Methods 0.000 description 12
- 230000018109 developmental process Effects 0.000 description 12
- 238000011065 in-situ storage Methods 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000004088 simulation Methods 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 201000001320 Atherosclerosis Diseases 0.000 description 11
- 230000033558 biomineral tissue development Effects 0.000 description 11
- UGSQEBVMGSXVSH-UHFFFAOYSA-L calcium;oxalate;dihydrate Chemical compound O.O.[Ca+2].[O-]C(=O)C([O-])=O UGSQEBVMGSXVSH-UHFFFAOYSA-L 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 210000002919 epithelial cell Anatomy 0.000 description 11
- 210000000709 aorta Anatomy 0.000 description 10
- 239000011248 coating agent Substances 0.000 description 10
- 238000001914 filtration Methods 0.000 description 10
- 210000004379 membrane Anatomy 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 102000016942 Elastin Human genes 0.000 description 9
- 108010014258 Elastin Proteins 0.000 description 9
- 102000003505 Myosin Human genes 0.000 description 9
- 108060008487 Myosin Proteins 0.000 description 9
- 229910052782 aluminium Inorganic materials 0.000 description 9
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 230000001086 cytosolic effect Effects 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 229920002549 elastin Polymers 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000011521 glass Substances 0.000 description 9
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 9
- 238000005070 sampling Methods 0.000 description 9
- 239000005149 Cholesterol Linoleate Substances 0.000 description 8
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 8
- NAACPBBQTFFYQB-UHFFFAOYSA-N Linolsaeure-cholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCC=CCCCCC)C2 NAACPBBQTFFYQB-UHFFFAOYSA-N 0.000 description 8
- 238000002583 angiography Methods 0.000 description 8
- 238000005452 bending Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- NAACPBBQTFFYQB-LJAITQKLSA-N cholesteryl linoleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/C\C=C/CCCCC)C1 NAACPBBQTFFYQB-LJAITQKLSA-N 0.000 description 8
- 230000001427 coherent effect Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000000670 limiting effect Effects 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 210000004940 nucleus Anatomy 0.000 description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 8
- 206010003210 Arteriosclerosis Diseases 0.000 description 7
- 208000000571 Fibrocystic breast disease Diseases 0.000 description 7
- 238000003332 Raman imaging Methods 0.000 description 7
- 208000011803 breast fibrocystic disease Diseases 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 238000007477 logistic regression Methods 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 150000003904 phospholipids Chemical class 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- 238000013334 tissue model Methods 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 229920002683 Glycosaminoglycan Polymers 0.000 description 6
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 210000002469 basement membrane Anatomy 0.000 description 6
- 238000012742 biochemical analysis Methods 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 210000000170 cell membrane Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000008878 coupling Effects 0.000 description 6
- 238000010168 coupling process Methods 0.000 description 6
- 238000005859 coupling reaction Methods 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000005286 illumination Methods 0.000 description 6
- 238000010348 incorporation Methods 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000000386 microscopy Methods 0.000 description 6
- 238000012544 monitoring process Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 5
- 206010028851 Necrosis Diseases 0.000 description 5
- 238000001530 Raman microscopy Methods 0.000 description 5
- 239000004809 Teflon Substances 0.000 description 5
- 229920006362 Teflon® Polymers 0.000 description 5
- 102000005937 Tropomyosin Human genes 0.000 description 5
- 108010030743 Tropomyosin Proteins 0.000 description 5
- 239000012472 biological sample Substances 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 208000030270 breast disease Diseases 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000001344 confocal Raman microscopy Methods 0.000 description 5
- 238000012937 correction Methods 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 230000004761 fibrosis Effects 0.000 description 5
- 239000005350 fused silica glass Substances 0.000 description 5
- 230000000762 glandular Effects 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 238000002608 intravascular ultrasound Methods 0.000 description 5
- 238000001000 micrograph Methods 0.000 description 5
- 230000017074 necrotic cell death Effects 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- LLQPHQFNMLZJMP-UHFFFAOYSA-N Fentrazamide Chemical compound N1=NN(C=2C(=CC=CC=2)Cl)C(=O)N1C(=O)N(CC)C1CCCCC1 LLQPHQFNMLZJMP-UHFFFAOYSA-N 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- 101710172711 Structural protein Proteins 0.000 description 4
- 210000003484 anatomy Anatomy 0.000 description 4
- 229910052786 argon Inorganic materials 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 238000002790 cross-validation Methods 0.000 description 4
- 238000013480 data collection Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 208000028715 ductal breast carcinoma in situ Diseases 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 238000007654 immersion Methods 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004660 morphological change Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 4
- 238000010223 real-time analysis Methods 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000037804 stenosis Diseases 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 4
- 229910052721 tungsten Inorganic materials 0.000 description 4
- 239000010937 tungsten Substances 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- 238000011179 visual inspection Methods 0.000 description 4
- OYHQOLUKZRVURQ-HZJYTTRNSA-M 9-cis,12-cis-Octadecadienoate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O OYHQOLUKZRVURQ-HZJYTTRNSA-M 0.000 description 3
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 3
- 229910016036 BaF 2 Inorganic materials 0.000 description 3
- 241000282994 Cervidae Species 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 3
- 206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 3
- 238000007476 Maximum Likelihood Methods 0.000 description 3
- RJECHNNFRHZQKU-UHFFFAOYSA-N Oelsaeurecholesterylester Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCC=CCCCCCCCC)C2 RJECHNNFRHZQKU-UHFFFAOYSA-N 0.000 description 3
- 239000004115 Sodium Silicate Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 240000006909 Tilia x europaea Species 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- 230000035508 accumulation Effects 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 244000309466 calf Species 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 3
- 235000021466 carotenoid Nutrition 0.000 description 3
- 150000001747 carotenoids Chemical class 0.000 description 3
- 239000004568 cement Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 208000026758 coronary atherosclerosis Diseases 0.000 description 3
- 208000031513 cyst Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- VEVRNHHLCPGNDU-MUGJNUQGSA-O desmosine Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(CC[C@H](N)C(O)=O)=C(CCC[C@H](N)C(O)=O)C(CC[C@H](N)C(O)=O)=C1 VEVRNHHLCPGNDU-MUGJNUQGSA-O 0.000 description 3
- 230000001066 destructive effect Effects 0.000 description 3
- 239000002019 doping agent Substances 0.000 description 3
- 201000007273 ductal carcinoma in situ Diseases 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 238000001506 fluorescence spectroscopy Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 3
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 229940049918 linoleate Drugs 0.000 description 3
- 238000002595 magnetic resonance imaging Methods 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000010453 quartz Substances 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 229910052911 sodium silicate Inorganic materials 0.000 description 3
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 230000007704 transition Effects 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- GTRMJEVFVTWDIU-KPNWGBFJSA-N (3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol;hydrate Chemical compound O.C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 GTRMJEVFVTWDIU-KPNWGBFJSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010058314 Dysplasia Diseases 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 102000016359 Fibronectins Human genes 0.000 description 2
- 108010067306 Fibronectins Proteins 0.000 description 2
- 229910000530 Gallium indium arsenide Inorganic materials 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229910003873 O—P—O Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920003350 Spectratech® Polymers 0.000 description 2
- 208000005475 Vascular calcification Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 208000036878 aneuploidy Diseases 0.000 description 2
- 231100001075 aneuploidy Toxicity 0.000 description 2
- -1 argon ion Chemical class 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000005389 breast carcinoma in situ Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 238000001148 chemical map Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000005253 cladding Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 239000004567 concrete Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000006059 cover glass Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 238000013144 data compression Methods 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 238000013171 endarterectomy Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000001634 microspectroscopy Methods 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 238000002135 phase contrast microscopy Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 238000003325 tomography Methods 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- INGWEZCOABYORO-UHFFFAOYSA-N 2-(furan-2-yl)-7-methyl-1h-1,8-naphthyridin-4-one Chemical compound N=1C2=NC(C)=CC=C2C(O)=CC=1C1=CC=CO1 INGWEZCOABYORO-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010048782 Breast calcifications Diseases 0.000 description 1
- 206010006189 Breast cancer in situ Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229910020366 ClO 4 Inorganic materials 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 244000118681 Iresine herbstii Species 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 238000000342 Monte Carlo simulation Methods 0.000 description 1
- 108010064719 Oxyhemoglobins Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241001440127 Phyllodes Species 0.000 description 1
- 208000002163 Phyllodes Tumor Diseases 0.000 description 1
- 239000004111 Potassium silicate Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 235000001466 Ribes nigrum Nutrition 0.000 description 1
- 241001312569 Ribes nigrum Species 0.000 description 1
- 241000219289 Silene Species 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229910052910 alkali metal silicate Inorganic materials 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000006117 anti-reflective coating Substances 0.000 description 1
- 229910052586 apatite Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000036523 atherogenesis Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000005284 basis set Methods 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000000701 chemical imaging Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 108010002255 deoxyhemoglobin Proteins 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000023077 detection of light stimulus Effects 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000005315 distribution function Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 239000012520 frozen sample Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000012623 in vivo measurement Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- PAZHGORSDKKUPI-UHFFFAOYSA-N lithium metasilicate Chemical compound [Li+].[Li+].[O-][Si]([O-])=O PAZHGORSDKKUPI-UHFFFAOYSA-N 0.000 description 1
- 229910052912 lithium silicate Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000011059 lobular neoplasia Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 238000002095 near-infrared Raman spectroscopy Methods 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 239000011824 nuclear material Substances 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 238000013488 ordinary least square regression Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000277 pancreatic duct Anatomy 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- 229940085991 phosphate ion Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 229910052913 potassium silicate Inorganic materials 0.000 description 1
- NNHHDJVEYQHLHG-UHFFFAOYSA-N potassium silicate Chemical compound [K+].[K+].[O-][Si]([O-])=O NNHHDJVEYQHLHG-UHFFFAOYSA-N 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940088336 primor Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000018448 secretion by cell Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000015590 smooth muscle cell migration Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010183 spectrum analysis Methods 0.000 description 1
- 239000005315 stained glass Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000004416 surface enhanced Raman spectroscopy Methods 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940072651 tylenol Drugs 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 238000007631 vascular surgery Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
- A61B5/0086—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters using infrared radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0075—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by spectroscopy, i.e. measuring spectra, e.g. Raman spectroscopy, infrared absorption spectroscopy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/414—Evaluating particular organs or parts of the immune or lymphatic systems
- A61B5/415—Evaluating particular organs or parts of the immune or lymphatic systems the glands, e.g. tonsils, adenoids or thymus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/4738—Diffuse reflection, e.g. also for testing fluids, fibrous materials
- G01N21/474—Details of optical heads therefor, e.g. using optical fibres
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
- A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
- A61B5/0091—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for mammography
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/45—For evaluating or diagnosing the musculoskeletal system or teeth
- A61B5/4519—Muscles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/4738—Diffuse reflection, e.g. also for testing fluids, fibrous materials
- G01N21/474—Details of optical heads therefor, e.g. using optical fibres
- G01N2021/4742—Details of optical heads therefor, e.g. using optical fibres comprising optical fibres
- G01N2021/4745—Fused bundle, i.e. for backscatter
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/47—Scattering, i.e. diffuse reflection
- G01N21/4738—Diffuse reflection, e.g. also for testing fluids, fibrous materials
- G01N21/474—Details of optical heads therefor, e.g. using optical fibres
- G01N2021/4752—Geometry
- G01N2021/4759—Annular illumination
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/65—Raman scattering
- G01N2021/653—Coherent methods [CARS]
- G01N2021/656—Raman microprobe
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Endoscopes (AREA)
Abstract
Description
[発明の詳細な説明]
本発明は組織のラマン分光法を使用するための系および方法に向けられる。適切な処置の指図において心臓専門医を補助するための血管造影カテーテルを使用するin vivoの応用のための系および方法を開発するための属性は、in vivo組織に低エネルギーレーザー光を送達しかつそれからの生じるラマンスペクトルシグネチャを効率的に収集することが可能なラマン分光法のための光ファイバープローブの開発である。好ましい態様のプローブは小型でありかつ微小光学の設計原理を使用する。
式中、B=PT(PPT)−1は目的の形態学的基礎スペクトルの較正ベクトルであり、また、Nはサンプル中のノイズである。
rtotal=C1r1+C2r2+C3r3・・・ (4)
[式中rはラマンスペクトルである]として、12種の生化学的成分のそれぞれについての部分的なフィットの寄与率(C1)を生成させるための単純な一次結合参照を使用して700〜1800cm−1のラマンシフト範囲でモデル化する。700〜1800cm−1のラマンシフト範囲は、この範囲がほとんどのスペクトル情報を含有するために選ばれる。
Ω’=πsin2(θ) (5)
かつ、光学軸に関して測定される収集の半角値(θ)について評価される。全部の光学系構成部品の反射および伝播の喪失(容易に至適化される因子)と一緒にファイバーカップリングの限界を無視すれば、系の収集能力はその最大の制限要素のスループットにより制限され、そしてこの量は系全体で保存される。
のように、光源から発射される光を近似する。
を使用して検定した。ゼロの値は該ベクトルが直交であることを示し、また、1の値はそれらが同一であることを意味する。
E=NB (11)
式中B=PT(PPT)−1は形態学的基礎スペクトルPの較正ベクトルであり、また、Nはサンプル中のノイズである。
Claims (68)
- 近位端および遠位端を有する光ファイバープローブ;
近位端で光源に接続されかつ遠位端に第一のフィルターを有するプローブ中の送達光ファイバー;
近位端で検出器に接続されかつ遠位端に第二のフィルターを有する、組織からのラマン散乱光を収集するプローブ中の収集光ファイバー;ならびに
送達ファイバーに接続された送達導波管および収集ファイバーに接続された収集導波管を包含するプローブの遠位端の光学系
を含んでなる組織測定用プローブ。 - 送達導波管がロッドを含んでなりかつ収集導波管がロッドの周囲に同心円状である円筒形チューブを含んでなる、請求項1に記載のプローブ。
- レンズが送達ファイバーおよび収集ファイバーに光学的に接続されたボールレンズを含んでなる、請求項1に記載のプローブ。
- 送達導波管を収集導波管から光学的に隔離するスリーブをさらに含んでなる、請求項1に記載のプローブ。
- 送達ファイバーの周囲に第一の半径で同心円状に配置された第一の複数の収集ファイバー、および送達ファイバーの周囲に第一の半径より大きい第二の半径で同心円状に配置された第二の複数の収集ファイバーをさらに含んでなる、請求項1に記載のプローブ。
- 2秒未満である収集時間をゲートする制御装置をさらに含んでなる、請求項1に記載のプローブ。
- 光学系が10mm未満の長さを有する、請求項1に記載のプローブ。
- 光学系が4mm未満の長さを有する、請求項1に記載のプローブ。
- 光源が750nmより長い波長を有する、請求項1に記載のプローブ。
- 光学系が放射状方向の光を送達かつ収集する、請求項1に記載のプローブ。
- プローブが心組織のスペクトルの特徴を測定する、請求項1に記載のプローブ。
- 遠位端が2mm若しくはそれ未満の直径を有する、請求項1に記載のプローブ。
- 送達光ファイバーの近位端に光学的に接続されている光源をさらに含んでなる、請求項1に記載のプローブ。
- 光学系が屈折光学素子を含んでなる、請求項1に記載のプローブ。
- 光学系が反射光学素子を含んでなる、請求項1に記載のプローブ。
- 光学系がボールレンズの一部分を含んでなる、請求項1に記載のプローブ。
- プローブが挿入されるチャンネルを有する内視鏡をさらに含んでなる、請求項1に記載のプローブ。
- 近位端、遠位端を有する光ファイバープローブ;
遠位端に第一のフィルターを有する、遠位端に放射を送達するための光源に近位端で接続されたプローブ中の送達光ファイバー;
近位端で検出器系に接続され、遠位端に第二のフィルターを有する、組織からのラマン散乱放射を収集するプローブ中の収集光ファイバー;ならびに
送達光ファイバーに接続された送達導波管ならびに収集光ファイバーおよびレンズ系に接続された収集導波管を包含するプローブの遠位端の光学レンズ系
を含んでなる、組織測定用の分光学的診断系。 - 送達導波管がロッドを含んでなりかつ収集導波管がロッドの周囲に同心円状である円筒形チューブを含んでなる、請求項18に記載の分光学的診断系。
- 送達導波管が第一の円筒形チューブを含んでなりかつ収集導波管が第一の円筒形チューブの周囲に同心円状である第二の円筒形チューブを含んでなる、請求項18に記載の分光学的診断系。
- レンズ系が、送達光ファイバーおよび収集光ファイバーに光学的に接続された楕円形アキシコンを含んでなる、請求項18に記載の分光学的診断系。
- 送達導波管を収集導波管から光学的に隔離するスリーブをさらに含んでなる、請求項18に記載の分光学的診断系。
- 送達ファイバーの周囲に第一の半径で同心円状に配置された第一の複数の収集ファイバー、および送達ファイバーの周囲に第一の半径より大きい第二の半径で同心円状に配置された第二の複数の収集ファイバーをさらに含んでなる、請求項18に記載の分光学的診断系。
- 周囲の画像を生成させる、請求項18に記載の分光学的診断系。
- 2秒未満である収集時間をゲートする制御装置をさらに含んでなる、請求項18に記載の分光学的診断系。
- 光学レンズ系が10mm未満の長さを有する、請求項18に記載の分光学的診断系。
- 光学レンズ系が4mm未満の長さを有する、請求項18に記載の分光学的診断系。
- 光源が750nmより長い波長を有する、請求項18に記載の分光学的診断系。
- 光学レンズ系が放射を放射状方向で送達かつ収集する、請求項18に記載の分光学的診断系。
- 近位端および遠位端を有する光ファイバープローブ;
光源の近位端に接続されかつ遠位端に第一のフィルターを有するプローブ中の最低1本の送達光ファイバー;
検出器の近位端に接続されかつ遠位端に第二のフィルターを有する、組織からのラマン散乱放射を収集するプローブ中の最低1本の収集光ファイバー;ならびに
送達光ファイバーに接続された送達導波管、収集光ファイバーに接続された収集導波管、ならびに反射および屈折光学素子の一つを包含するプローブの遠位端の光学系
を含んでなる、測定用の分光学的カテーテル系。 - 光ファイバープローブの周囲に配置された膨張可能なバルーンをさらに含んでなる、請求項30に記載の分光学的カテーテル系。
- バルーンを膨張させるためのチャンネルをさらに含んでなる、請求項30に記載の分光学的カテーテル系。
- 送達導波管がロッドを含んでなりかつ収集導波管がロッドの周囲で同心円状である円筒形チューブを含んでなる、請求項30に記載の分光学的カテーテル系。
- 送達導波管が第一の円筒形チューブを含んでなりかつ収集導波管が第一の円筒形チューブの周囲で同心円状である第二の円筒形チューブを含んでなる、請求項30に記載の分光学的カテーテル系。
- 光学素子が、送達光ファイバーおよび収集光ファイバーに光学的に接続された楕円形アキシコンを含んでなる、請求項30に記載の分光学的カテーテル系。
- 送達導波管を収集導波管から光学的に隔離するスリーブをさらに含んでなる、請求項30に記載の分光学的カテーテル系。
- 送達ファイバーの周囲に第一の半径で同心円状に配置された第一の複数の収集ファイバー、および送達ファイバーの周囲に第一の半径より大きい第二の半径で同心円状に配置された第二の複数の収集ファイバーをさらに含んでなる、請求項30に記載の分光学的カテーテル系。
- 周囲の画像を生成させる、請求項30に記載の分光学的カテーテル系。
- 光学素子が、送達光ファイバーおよび収集光ファイバーに光学的に接続されたボールレンズを含んでなる、請求項30に記載の分光学的カテーテル系。
- 2秒未満である収集時間をゲートする制御装置をさらに含んでなる、請求項30に記載の分光学的カテーテル系。
- 近位端、遠位端、近位端で光源に接続されかつ遠位端に第一のフィルターを有するプローブ中の最低1本の送達光ファイバー、および近位端で検出器に接続されかつ遠位端に第二のフィルターを有するサンプルからのラマン散乱放射を収集するプローブ中の最低1本の収集光ファイバーを有する光ファイバープローブを提供すること;そして
送達光ファイバーに接続された送達導波管および収集光ファイバーに接続された収集導波管を包含するプローブの遠位端の光学系を用いてサンプルからの光を収集すること
を含んでなる、サンプルの測定方法。 - 光ファイバープローブの周囲に配置されたバルーンを膨張させることをさらに含んでなる、請求項41に記載の方法。
- プローブ中のチャンネルを通してバルーンを膨張させることをさらに含んでなる、請求項42に記載の方法。
- ロッドを含んでなる送達導波管を提供すること、およびロッドの周囲で同心円状である円筒形チューブを含んでなる収集導波管を提供することをさらに含んでなる、請求項41に記載の方法。
- 第一の円筒形チューブを提供すること、および第一の円筒形チューブの周囲で同心円状である第二の円筒形チューブを含んでなる収集導波管を提供することをさらに含んでなる、請求項41に記載の方法。
- 送達光ファイバーおよび収集光ファイバーに光学的に接続された楕円形アキシコンを包含する光学素子を提供することをさらに含んでなる、請求項41に記載の方法。
- 送達導波管を収集導波管から光学的に隔離するスリーブを提供することをさらに含んでなる、請求項41に記載の方法。
- 送達ファイバーの周囲に第一の半径で同心円状に配置された第一の複数の収集ファイバー、および送達ファイバーの周囲に第一の半径より大きい第二の半径で同心円状に配置された第二の複数の収集ファイバーを提供することをさらに含んでなる、請求項41に記載の方法。
- 周囲の画像を生成させることをさらに含んでなる、請求項41に記載の方法。
- 送達光ファイバーおよび収集光ファイバーに光学的に接続されているボールレンズを用いて光を伝播させることをさらに含んでなる、請求項41に記載の方法。
- 2秒未満である収集時間を制御することをさらに含んでなる、請求項41に記載の方法。
- プローブの遠位端を回転させて光を複数の方向で放射状に向けることをさらに含んでなる、請求項41に記載の方法。
- 組織からのラマンデータの処理方法をさらに含んでなる、請求項41に記載の方法。
- 癌組織を診断するためにデータを処理することをさらに含んでなる、請求項53に記載の方法。
- スペクトルデータのリアルタイムin vivo解析を実施することをさらに含んでなる、請求項41に記載の方法。
- 65ミクロン未満の厚さを有する動脈の線維性被膜を検出することをさらに含んでなる、請求項41に記載の方法。
- 脂質プール、炎症細胞、泡沫細胞若しくは血栓を検出することをさらに含んでなる、請求項41に記載の方法。
- 1.5mm若しくはそれ未満の直径を有するプローブを用いて検出することをさらに含んでなる、請求項41に記載の方法。
- 体腔若しくは動脈中にプローブを挿入すること、およびプローブを抜去する際にプローブを回転させて該体腔若しくは動脈を走査することをさらに含んでなる、請求項41に記載の方法。
- 乳房組織を診断することをさらに含んでなる、請求項41に記載の方法。
- 針を通してプローブを挿入することをさらに含んでなる、請求項41に記載の方法。
- プローブの遠位端の鏡上にハーフボールレンズを提供することをさらに含んでなる、請求項41に記載の方法。
- 近位端で光源に接続されかつ第一のフィルターを有する送達路;
分配要素および検出器を包含する検出器系に近位端で接続されかつ第二のフィルターを有する、組織からのラマン散乱光を収集する収集路、ならびに
検出器系からのラマンスペクトルデータを処理するデータプロセッサ
を含んでなる、組織測定用の顕微鏡系。 - 電荷結合素子センサーをさらに含んでなる請求項63に記載の系。
- データプロセッサが複数の組織成分の存在を決定する、請求項63に記載の系。
- CCDカメラをさらに含んでなる請求項63に記載の系。
- レーザー光源、シャッターおよび検出器を制御する制御装置をさらに含んでなる、請求項63に記載の系。
- 400〜2000cm−1の範囲のラマンシグナルを検出することをさらに含んでなる、請求項41に記載の系。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37019702P | 2002-04-05 | 2002-04-05 | |
US10/178,062 US7647092B2 (en) | 2002-04-05 | 2002-06-21 | Systems and methods for spectroscopy of biological tissue |
PCT/US2003/010307 WO2003087793A1 (en) | 2002-04-05 | 2003-04-04 | Systems and methods for spectroscopy of biological tissue |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010136655A Division JP2010249835A (ja) | 2002-04-05 | 2010-06-15 | 生物学的組織の分光法のための系および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005522293A true JP2005522293A (ja) | 2005-07-28 |
JP2005522293A5 JP2005522293A5 (ja) | 2006-05-25 |
JP4588324B2 JP4588324B2 (ja) | 2010-12-01 |
Family
ID=28677945
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003584690A Expired - Fee Related JP4588324B2 (ja) | 2002-04-05 | 2003-04-04 | 組織測定用プローブ |
JP2010136655A Pending JP2010249835A (ja) | 2002-04-05 | 2010-06-15 | 生物学的組織の分光法のための系および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010136655A Pending JP2010249835A (ja) | 2002-04-05 | 2010-06-15 | 生物学的組織の分光法のための系および方法 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1495309A1 (ja) |
JP (2) | JP4588324B2 (ja) |
AU (1) | AU2003230799A1 (ja) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004294109A (ja) * | 2003-03-25 | 2004-10-21 | Institute Of Physical & Chemical Research | ラマンプローブ及びそれを用いたラマン散乱計測装置 |
JP2007083055A (ja) * | 2005-09-21 | 2007-04-05 | Siemens Ag | 光コヒーレンス断層画像化システム |
JP2008523375A (ja) * | 2004-12-09 | 2008-07-03 | ザ サイエンス アンド テクノロジー ファシリティーズ カウンシル | 深さ選択的ラマン分光法のための装置 |
JP2009008481A (ja) * | 2007-06-27 | 2009-01-15 | Olympus Corp | 画像処理装置および画像処理プログラム |
JP2009066125A (ja) * | 2007-09-12 | 2009-04-02 | Canon Inc | 測定装置 |
JP2009540322A (ja) * | 2006-06-16 | 2009-11-19 | レニショウ パブリック リミテッド カンパニー | 分光解析方法 |
WO2010103661A1 (ja) * | 2009-03-13 | 2010-09-16 | 京都府公立大学法人 | ラマン散乱を用いた生体組織イメージング |
JP2010540958A (ja) * | 2007-10-01 | 2010-12-24 | ビオレソナトル・アクチボラゲット | 影響を受けない材料分析の方法および集成装置 |
JP4833283B2 (ja) * | 2005-05-27 | 2011-12-07 | ネイダーランゼ、オルガニザティー、ボー、トゥーゲパストナトゥールウェテンシャッペルーク、オンダーツォーク、ティーエヌオー | ファントム装置 |
JP2012189322A (ja) * | 2011-03-08 | 2012-10-04 | Olympus Corp | 液状生体ファントム及び液状生体ファントムの作製方法 |
JP2012251976A (ja) * | 2011-06-07 | 2012-12-20 | Sharp Corp | 検出装置 |
JP2013514520A (ja) * | 2009-12-17 | 2013-04-25 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | ラマン分光法によるインビボでの組織の特徴付けのための装置および方法 |
WO2013136664A1 (ja) | 2012-03-13 | 2013-09-19 | コニカミノルタ株式会社 | プローブ |
JP2013536947A (ja) * | 2010-09-01 | 2013-09-26 | ケーエルエー−テンカー コーポレイション | 集光光学系 |
JP2014224771A (ja) * | 2013-05-16 | 2014-12-04 | 三菱重工業株式会社 | 燃料ガス計測装置及び方法 |
JP5772831B2 (ja) * | 2010-12-16 | 2015-09-02 | コニカミノルタ株式会社 | プローブ |
JP2015526135A (ja) * | 2012-07-02 | 2015-09-10 | ナショナル ユニヴァーシティー オブ シンガポール | 光ファイバーラマン分光法を利用する内視鏡検査でのリアルタイム癌診断に関連する方法 |
JP5831456B2 (ja) * | 2010-10-26 | 2015-12-09 | コニカミノルタ株式会社 | プローブ |
JP2017129389A (ja) * | 2016-01-19 | 2017-07-27 | 国立大学法人島根大学 | ラマン散乱光の観測方法、ラマン散乱光の観測装置及びプログラム |
WO2018116363A1 (ja) * | 2016-12-19 | 2018-06-28 | オリンパス株式会社 | ラマンプローブおよびラマンスペクトル測定装置 |
JP2020509400A (ja) * | 2017-01-27 | 2020-03-26 | レニショウ パブリック リミテッド カンパニーRenishaw Public Limited Company | 直接のレーザー書き込みおよびケミカルエッチング並びに光学デバイス |
US11478151B2 (en) | 2011-12-14 | 2022-10-25 | The Trustees Of The University Of Pennsylvania | Fiber optic flow and oxygenation monitoring using diffuse correlation and reflectance |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5389884B2 (ja) * | 2011-09-30 | 2014-01-15 | 富士フイルム株式会社 | 内視鏡用照明光学系及び照明装置 |
WO2013061590A1 (ja) * | 2011-10-25 | 2013-05-02 | コニカミノルタアドバンストレイヤー株式会社 | 光学プローブ及びその製造方法 |
JP5733163B2 (ja) * | 2011-11-10 | 2015-06-10 | コニカミノルタ株式会社 | プローブの製造方法 |
SG11201501082RA (en) * | 2012-08-16 | 2015-03-30 | Univ Singapore | Diagnostic instrument and methods relating to raman spectroscopy |
JP6006036B2 (ja) * | 2012-08-17 | 2016-10-12 | オリンパス株式会社 | 分光スペクトル解析方法 |
JP6082273B2 (ja) * | 2013-02-25 | 2017-02-15 | 日本板硝子株式会社 | 蛍光検出装置 |
JP6294614B2 (ja) * | 2013-05-08 | 2018-03-14 | 有限会社マイテック | 癌関連物質の定量方法 |
JP6273470B2 (ja) * | 2013-05-10 | 2018-02-07 | ナノフォトン株式会社 | 分子振動の表示方法 |
JP6103700B2 (ja) * | 2013-05-15 | 2017-03-29 | 京都府公立大学法人 | ラマン散乱を用いた心臓組織の識別方法及び装置 |
WO2015128946A1 (ja) | 2014-02-25 | 2015-09-03 | オリンパス株式会社 | 分光スペクトル解析方法 |
CN103932680A (zh) * | 2014-04-15 | 2014-07-23 | 广州玖玖伍捌信息科技有限公司 | 一种人体肿瘤复发监测及热疗一体系统 |
FR3024546B1 (fr) * | 2014-07-29 | 2018-08-24 | Universite De Reims Champagne-Ardenne | Procede de detection et de quantification de la fibrose |
WO2016121811A1 (ja) * | 2015-01-29 | 2016-08-04 | 富士フイルム株式会社 | 画像処理装置及び画像処理方法、並びに内視鏡システム |
JP6336949B2 (ja) * | 2015-01-29 | 2018-06-06 | 富士フイルム株式会社 | 画像処理装置及び画像処理方法、並びに内視鏡システム |
JP6428825B2 (ja) * | 2017-03-29 | 2018-11-28 | セイコーエプソン株式会社 | 検出装置 |
US11672425B2 (en) | 2018-02-15 | 2023-06-13 | Speclipse, Inc. | Stand-alone apparatus and methods for in vivo detection of tissue malignancy using laser spectroscopy |
AU2019437773B2 (en) | 2019-03-22 | 2021-10-28 | Speclipse, Inc. | Diagnostic method using laser induced breakdown spectroscopy, and diagnostic device for performing same |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK130586A (da) * | 1985-03-22 | 1986-09-23 | Massachusetts Inst Technology | Laser-kateter til indfoering i arterier |
DE3673378D1 (de) * | 1986-01-30 | 1990-09-13 | Dow Chemical Co | Faseroptische sonde. |
WO1989002718A1 (en) * | 1987-09-24 | 1989-04-06 | Massachusetts Institute Of Technology | Catheter system for imaging |
US5615673A (en) * | 1995-03-27 | 1997-04-01 | Massachusetts Institute Of Technology | Apparatus and methods of raman spectroscopy for analysis of blood gases and analytes |
JP2000515407A (ja) * | 1996-08-02 | 2000-11-21 | ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム | 上皮被覆内臓組織の特徴付けのための方法および装置 |
JPH10267846A (ja) * | 1997-03-27 | 1998-10-09 | Jeol Ltd | レーザ照射/取り込み光学装置 |
JP4486743B2 (ja) * | 2000-10-31 | 2010-06-23 | 株式会社町田製作所 | 血管内壁の付着物質の分析システム |
-
2003
- 2003-04-04 JP JP2003584690A patent/JP4588324B2/ja not_active Expired - Fee Related
- 2003-04-04 AU AU2003230799A patent/AU2003230799A1/en not_active Abandoned
- 2003-04-04 EP EP03723896A patent/EP1495309A1/en not_active Withdrawn
-
2010
- 2010-06-15 JP JP2010136655A patent/JP2010249835A/ja active Pending
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004294109A (ja) * | 2003-03-25 | 2004-10-21 | Institute Of Physical & Chemical Research | ラマンプローブ及びそれを用いたラマン散乱計測装置 |
JP2008523375A (ja) * | 2004-12-09 | 2008-07-03 | ザ サイエンス アンド テクノロジー ファシリティーズ カウンシル | 深さ選択的ラマン分光法のための装置 |
JP4833283B2 (ja) * | 2005-05-27 | 2011-12-07 | ネイダーランゼ、オルガニザティー、ボー、トゥーゲパストナトゥールウェテンシャッペルーク、オンダーツォーク、ティーエヌオー | ファントム装置 |
JP2007083055A (ja) * | 2005-09-21 | 2007-04-05 | Siemens Ag | 光コヒーレンス断層画像化システム |
JP2009540322A (ja) * | 2006-06-16 | 2009-11-19 | レニショウ パブリック リミテッド カンパニー | 分光解析方法 |
JP2009008481A (ja) * | 2007-06-27 | 2009-01-15 | Olympus Corp | 画像処理装置および画像処理プログラム |
JP2009066125A (ja) * | 2007-09-12 | 2009-04-02 | Canon Inc | 測定装置 |
JP2010540958A (ja) * | 2007-10-01 | 2010-12-24 | ビオレソナトル・アクチボラゲット | 影響を受けない材料分析の方法および集成装置 |
WO2010103661A1 (ja) * | 2009-03-13 | 2010-09-16 | 京都府公立大学法人 | ラマン散乱を用いた生体組織イメージング |
JP5372137B2 (ja) * | 2009-03-13 | 2013-12-18 | 京都府公立大学法人 | ラマン散乱を用いた生体組織イメージング |
JP2013514520A (ja) * | 2009-12-17 | 2013-04-25 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | ラマン分光法によるインビボでの組織の特徴付けのための装置および方法 |
JP2013536947A (ja) * | 2010-09-01 | 2013-09-26 | ケーエルエー−テンカー コーポレイション | 集光光学系 |
JP5831456B2 (ja) * | 2010-10-26 | 2015-12-09 | コニカミノルタ株式会社 | プローブ |
US9456753B2 (en) | 2010-12-16 | 2016-10-04 | Konica Minolta, Inc. | Probe |
JP5772831B2 (ja) * | 2010-12-16 | 2015-09-02 | コニカミノルタ株式会社 | プローブ |
JP2012189322A (ja) * | 2011-03-08 | 2012-10-04 | Olympus Corp | 液状生体ファントム及び液状生体ファントムの作製方法 |
JP2012251976A (ja) * | 2011-06-07 | 2012-12-20 | Sharp Corp | 検出装置 |
US11478151B2 (en) | 2011-12-14 | 2022-10-25 | The Trustees Of The University Of Pennsylvania | Fiber optic flow and oxygenation monitoring using diffuse correlation and reflectance |
WO2013136664A1 (ja) | 2012-03-13 | 2013-09-19 | コニカミノルタ株式会社 | プローブ |
US9867557B2 (en) | 2012-03-13 | 2018-01-16 | Konica Minolta, Inc. | Probe |
JP2015526135A (ja) * | 2012-07-02 | 2015-09-10 | ナショナル ユニヴァーシティー オブ シンガポール | 光ファイバーラマン分光法を利用する内視鏡検査でのリアルタイム癌診断に関連する方法 |
JP2014224771A (ja) * | 2013-05-16 | 2014-12-04 | 三菱重工業株式会社 | 燃料ガス計測装置及び方法 |
JP2017129389A (ja) * | 2016-01-19 | 2017-07-27 | 国立大学法人島根大学 | ラマン散乱光の観測方法、ラマン散乱光の観測装置及びプログラム |
WO2018116363A1 (ja) * | 2016-12-19 | 2018-06-28 | オリンパス株式会社 | ラマンプローブおよびラマンスペクトル測定装置 |
US10670530B2 (en) | 2016-12-19 | 2020-06-02 | Olympus Corporation | Raman probe and Raman spectrum measuring device |
JP2020509400A (ja) * | 2017-01-27 | 2020-03-26 | レニショウ パブリック リミテッド カンパニーRenishaw Public Limited Company | 直接のレーザー書き込みおよびケミカルエッチング並びに光学デバイス |
Also Published As
Publication number | Publication date |
---|---|
EP1495309A1 (en) | 2005-01-12 |
JP2010249835A (ja) | 2010-11-04 |
JP4588324B2 (ja) | 2010-12-01 |
AU2003230799A1 (en) | 2003-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4588324B2 (ja) | 組織測定用プローブ | |
US20170202462A1 (en) | Systems and methods for spectroscopy of biological tissue | |
EP2325623A2 (en) | Systems and methods for spectroscopy of biological tissue | |
CA2658811C (en) | Multi modal spectroscopy | |
JP4870356B2 (ja) | 組織を測定するための高波数ラマン分光法の使用 | |
US8243269B2 (en) | Raman spectral analysis of sub-surface tissues and fluids | |
US6697665B1 (en) | Systems and methods of molecular spectroscopy to provide for the diagnosis of tissue | |
JP4516217B2 (ja) | 組織の偏光散乱分光法 | |
Bodanese et al. | Differentiating normal and basal cell carcinoma human skin tissues in vitro using dispersive Raman spectroscopy: a comparison between principal components analysis and simplified biochemical models | |
US20090326385A1 (en) | Obtaining optical tissue properties | |
US20060281068A1 (en) | Cytological methods for detecting a disease condition such as malignancy by Raman spectroscopic imaging | |
JP3923080B2 (ja) | 光学的微細プローベ及び材料のスペクトル分析方法 | |
AU9693298A (en) | Method for measuring tissue morphology | |
US20120200850A1 (en) | Cytological methods for detecting a condition such as transplant efficiency by raman spectroscopic imaging | |
Vasquez et al. | Multimodal scanning microscope combining optical coherence tomography, Raman spectroscopy and fluorescence lifetime microscopy for mesoscale label-free imaging of tissue | |
Kandurova et al. | Optical fine-needle biopsy approach for intraoperative multimodal diagnostics in minimally invasive abdominal surgery | |
Krafft et al. | Near infrared Raman spectroscopy to study the composition of human brain tissue and tumors | |
Uckermann et al. | Optical biochemical imaging: potential new applications in neuro-oncology | |
Bandzeviciute et al. | Fast and label-free intraoperative discrimination of malignant pancreatic tissue by attenuated total reflection infrared spectroscopy | |
WO2012127378A1 (en) | An apparatus for optical analysis of an associated tissue sample | |
Motz | Development of in vivo Raman spectroscopy of atherosclerosis | |
Curtis | Comparing coherent and spontaneous Raman modalities for the investigation of gastrointestinal cancers. | |
Desroches | Sonde de biopsie optique afin d'améliorer la sécurité et la précision de diagnostic des biopsies neurochirurgicales | |
Chau | Development of an intracoronary Raman spectroscopy | |
Krafft et al. | Raman Spectroscopy to Solve Unmet Needs in Histopathology |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060403 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060403 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081101 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090407 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090707 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090714 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091006 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100315 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100323 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100615 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100817 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100908 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130917 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |